PTC Therapeutics' phase 3 trial of its experimental drug ataluren remains open to boys with Duchenne or Becker MD caused by premature stop codon mutations
PTC Therapeutics, a South Plainfield, N.J., biopharmaceutical company, wants to remind families affected by Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) caused by specific genetic mutations that its phase 3 trial of
MDA-supported biotechnology company Summit PLC and the University of Oxford will collaborate on development of utrophin modulators to treat Duchenne/Becker MD
MDA-supported biotechnology company Summit PLC has entered into a collaboration with the University of Oxford (United Kingdom) for continued development of utrophin modulators to treat Duchenne muscular dystrophy (DMD) and possibly Becker muscular dystrophy (BMD).
Biotech company Prosensa says an analysis of drisapersen trials in Duchenne muscular dystrophy and a DMD natural history study will guide future exon-skipping drug trials
In a Nov.
A study to determine the natural history and outcome measures for clinical trials in Becker MD and sporadic (nongenetic) inclusion-body myositis is open in Ohio
A study to determine the best outcome measures — ways to evaluate the effects of a treatment — for use in clinical studies in Becker muscular dystrophy (BMD) and sporadic (nongenetic) inclusion-body myositis (sIBM) is underway at Nationwide Children's Hospital in Columbus, Ohio, under the supervision of neurologist Jerry Mendell working with physical therapists Linda Lowes and
Prosensa and GlaxoSmithKline aim to enroll 250 participants in a study to determine the usual progression of Duchenne muscular dystrophy and aid clinical trials
Dutch biotechnology company Prosensa and multinational pharmaceutical company GlaxoSmithKline (GSK) are seeking participants with Duchenne muscular dystrophy (DMD) who are 3-18 years old for a large-scale study of the disorder's "natural history" (usual course over time).
An MDA Venture Philanthropy grant of $500,000 to Halo Therapeutics will support the development of HT-100, an experimental drug for Duchenne muscular dystrophy
MDA has awarded a grant of $500,000 to Newton, Mass., biopharmaceutical company Halo Therapeutics for development of HT-100, an experimental drug for Duchenne muscular dystrophy (DMD).
Summit PLC, an MDA-supported biotechnology company in the UK, has received approval to test its experimental DMD drug SMT C1100 in boys with this disorder
Update (Dec. 9, 2013): Summit announced in a Dec.